Tc 99m P215

Drug Profile

Tc 99m P215

Alternative Names: P215

Latest Information Update: 11 Sep 2006

Price : $50

At a glance

  • Originator Bayer Schering Pharma
  • Class Organotechnetium compounds; Peptide diagnostics; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Technetium compounds
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Atherosclerosis

Most Recent Events

  • 11 Sep 2006 Discontinued - Phase-II for Atherosclerosis diagnosis in USA (unspecified route)
  • 09 Oct 2001 No development reported - Phase-II for Atherosclerosis diagnosis in USA (unspecified route)
  • 16 Nov 1999 Diatide has been acquired by Schering AG
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top